Ishara Investments LP
Ishara Investments LP reported 41 US-listed holdings worth $136.1 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Acadia Pharmaceuticals Inc. (7.6%), Xeris Biopharma Holdings Inc. (7.2%) and Biomarin Pharmaceutical Inc. (6.0%). Against the quarter before, it opened 16 positions, added to 13, trimmed 8 and sold out of 11.
Reported holdings$136.1M+37.4% on Q1 2026
Positions41+5 on Q1 2026
The largest ten51.0%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
OpenedAdded toHeldTrimmed
The 14 largest of its 41 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +23.4% over the 2 quarters to 30 June 2026, against +9.5% for the S&P 500.
Its reported holdingsThe S&P 500
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Opened 16Added 13Held 4Trimmed 8Sold out 11
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 16
- Agios Pharmaceuticals Inc. AGIO$6.1 million
- Insmed Inc. INSM$5.5 million
- Crinetics Pharmaceuticals in CRNX$5.4 million
- Tonix Pharmaceuticals Hldg Co. Com New TNXP$4.3 million
- Bridgebio Pharma Inc. BBIO$4.3 million
- Kura Oncology Inc. KURA$3.0 million
- Cytokinetics Inc. CYTK$2.8 million
- Nuvation Bio Inc. NUVB$2.1 million
and 8 more in the table below
Added to 13
- Acadia Pharmaceuticals Inc. ACAD+287,000 shares · +233%
- Annexon Inc. ANNX+645,750 shares · +371%
- Biomarin Pharmaceutical Inc. BMRN+61,500 shares · +75%
- Xeris Biopharma Holdings Inc. XERS+205,000 shares · +20%
- Vaxcyte Inc. PCVX+24,600 shares · +43%
- DBV Technologies S A DBVT+82,000 shares · +80%
- Contineum Therapeutics Inc. CTNM+63,000 shares · +44%
- Ultragenyx Pharmaceutical in RARE+30,750 shares · +18%
and 5 more in the table below
Trimmed 8
- Axsome Therapeutics Inc. AXSM-24,600 shares · -60%
- Silence Therapeutics PLC SLN-85,150 shares · -61%
- Vera Therapeutics Inc. VERA-71,750 shares · -88%
- Travere Therapeutics Inc. TVTX-28,700 shares · -26%
- Scholar Rock Holding Corporation SRRK-26,650 shares · -46%
- Immatics N.V IMTX-123,000 shares · -80%
- Zentalis Pharmaceuticals Inc. ZNTL-205,000 shares · -17%
- Beam Therapeutics Inc. BEAM-16,400 shares · -29%
Sold out of 11
- Kalvista Pharmaceuticals Inc. KALV$5.6 million last quarter
- Amicus Therapeutics Inc. FOLD$5.3 million last quarter
- Verastem Inc. VSTM$4.3 million last quarter
- Arrowhead Pharmaceuticals, Inc. ARWR$3.5 million last quarter
- Moonlake Immunotherapeutics MLTX$3.2 million last quarter
- Ardelyx Inc. ARDX$2.7 million last quarter
- Catalyst Pharmaceuticals Inc. CPRX$2.0 million last quarter
- Ligand Pharmaceuticals Inc. LGND$1.6 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Acadia Pharmaceuticals Inc. ACAD | 410.0K | $10.4 million | 7.62% | +287.0K |
| Xeris Biopharma Holdings Inc. XERS | 1.2M | $9.7 million | 7.16% | +205.0K |
| Biomarin Pharmaceutical Inc. BMRN | 143.5K | $8.2 million | 6.03% | +61.5K |
| Praxis Precision Medicines I PRAX | 22.6K | $7.5 million | 5.55% | no change |
| Ultragenyx Pharmaceutical in RARE | 205.0K | $6.8 million | 5.03% | +30.8K |
| Agios Pharmaceuticals Inc. AGIO | 164.0K | $6.1 million | 4.47% | new |
| Insmed Inc. INSM | 51.2K | $5.5 million | 4.01% | new |
| Crinetics Pharmaceuticals in CRNX | 143.5K | $5.4 million | 3.95% | new |
| Zentalis Pharmaceuticals Inc. ZNTL | 1.0M | $5.0 million | 3.65% | -205.0K |
| Vaxcyte Inc. PCVX | 82.0K | $4.8 million | 3.50% | +24.6K |
| Annexon Inc. ANNX | 820.0K | $4.7 million | 3.44% | +645.8K |
| Travere Therapeutics Inc. TVTX | 82.0K | $4.7 million | 3.42% | -28.7K |
| Tonix Pharmaceuticals Hldg Co. Com New TNXP | 338.2K | $4.3 million | 3.17% | new |
| Bridgebio Pharma Inc. BBIO | 57.4K | $4.3 million | 3.14% | new |
| Axsome Therapeutics Inc. AXSM | 16.4K | $4.0 million | 2.95% | -24.6K |
| Contineum Therapeutics Inc. CTNM | 205.0K | $3.4 million | 2.47% | +63.0K |
| Lexicon Pharmaceuticals Inc. LXRX | 1.3M | $3.1 million | 2.24% | +369.0K |
| Kura Oncology Inc. KURA | 276.8K | $3.0 million | 2.23% | new |
| DBV Technologies S A DBVT | 184.5K | $3.0 million | 2.22% | +82.0K |
| Genmab A/S GMAB | 102.5K | $2.8 million | 2.07% | +20.5K |
| Cytokinetics Inc. CYTK | 32.8K | $2.8 million | 2.05% | new |
| Mineralys Therapeutics Inc. MLYS | 102.5K | $2.8 million | 2.03% | +20.5K |
| Silence Therapeutics PLC SLN | 55.4K | $2.4 million | 1.79% | -85.2K |
| Nuvation Bio Inc. NUVB | 369.0K | $2.1 million | 1.54% | new |
| Wave Life Sciences Ltd WVE | 328.0K | $1.9 million | 1.40% | new |
| Nektar Therapeutics NKTR | 26.6K | $1.9 million | 1.37% | new |
| Scholar Rock Holding Corporation SRRK | 30.8K | $1.7 million | 1.24% | -26.6K |
| Enliven Therapeutics Inc. ELVN | 32.8K | $1.7 million | 1.22% | new |
| Alnylam Pharmaceuticals Inc ALNY | 5.1K | $1.5 million | 1.13% | no change |
| Beam Therapeutics Inc. BEAM | 41.0K | $1.4 million | 1.03% | -16.4K |
| Sionna Therapeutics Inc SION | 123.0K | $1.4 million | 0.99% | +73.8K |
| Oric Pharmaceuticals Inc. ORIC | 123.0K | $1.3 million | 0.98% | +20.5K |
| Newamsterdam Pharma Company NAMS | 36.9K | $1.3 million | 0.92% | no change |
| Vertex Pharmaceuticals Inc. VRTX | 2.5K | $1.2 million | 0.90% | new |
| Ars Pharmaceuticals Inc. SPRY | 143.5K | $1.1 million | 0.84% | new |
| Monopar Therapeutics Inc. MNPR | 12.3K | $1.1 million | 0.84% | new |
| Erasca Inc. ERAS | 41.0K | $751,120 | 0.55% | new |
| Vera Therapeutics Inc. VERA | 10.2K | $439,828 | 0.32% | -71.8K |
| Immatics N.V IMTX | 30.8K | $311,498 | 0.23% | -123.0K |
| Mereo Biopharma Group PLC MREO | 768.8K | $244,232 | 0.18% | new |
| Gossamer Bio Inc. GOSS | 820.0K | $134,972 | 0.10% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.